Enhancing Antitumour Nanovaccine Efficacy via Integrated Cholesterol Modulation in Situ
Researchers have created a nanovaccine, NPCM‑OT, that simultaneously delivers tumor antigens and depletes cholesterol from dendritic cell membranes. The cholesterol reduction reshapes lipid microdomains, enhancing immune‑synapse formation and CD8⁺ T‑cell activation. In multiple mouse tumor models, the vaccine showed both preventive and therapeutic efficacy, markedly slowing tumor growth. The work demonstrates that modulating dendritic cell membrane composition can boost cancer vaccine performance.
The Hallmarks of Cancer: 25 Years Guiding Discovery and Therapy
Twenty‑five years after the original six Hallmarks of Cancer were proposed, Douglas Hanahan updates the framework to incorporate new hallmarks such as deregulated metabolism, immune evasion, and the tumor microenvironment. Advances in genomics, single‑cell and spatial profiling have deepened insight...
Targeting Genomic Instability in Cancer
Genomic instability fuels cancer evolution and simultaneously creates therapeutic vulnerabilities. Decades of genotoxic chemotherapy and radiation have given way to precision approaches that exploit DNA‑damage response (DDR) defects, most notably PARP inhibitors for BRCA‑mutated tumors. The pipeline now includes dozens...
Singapore: AI Biochip Speeds Up Genetic Marker Detection to 20 Minutes
Scientists at Nanyang Technological University have unveiled an AI‑powered biochip that identifies disease‑linked microRNA markers in just 20 minutes using a single drop of blood. The nanophotonic chip amplifies fluorescent signals, while deep‑learning algorithms analyze thousands of nanocavities in real...
Color Test 'Sniffs Out' Dangerous Staph Strains Fast
Researchers at RMIT University have created a rapid, low‑cost color‑changing test that distinguishes virulent and antibiotic‑resistant Staphylococcus aureus strains. The assay uses gold nanozyme particles and DNA aptamer binders to generate strain‑specific color fingerprints, functioning effectively in simulated wound fluid....
PrecisionLife and Ovation Target GLP-1 Response Variability with New Biomarker-Driven Collaboration
PrecisionLife and Ovation.io have teamed up to convert multi‑omic analyses of GLP‑1 receptor agonist use into predictive biomarker tools, including laboratory‑developed tests and a consumer DNA test. Early findings reveal separate biological drivers for glycemic control (HbA1c reduction) and weight...
Spain Plants US$200m Flag in Boston with Debut US Biotech Fund
Spain has unveiled a $200 million venture‑capital fund based in Boston, anchored by $57 million of public seed capital. The fund will back Spanish life‑science startups seeking to scale within the U.S. ecosystem and co‑invest in select American biotech firms. A new...
Fujifilm Biotechnologies Opens New QC Lab in Denmark
Fujifilm Biotechnologies has opened a 2,000‑square‑meter GMP‑approved quality control laboratory at its Hillerød, Denmark site. The facility, designed for bioassay and virology work, will accommodate roughly 100 quality‑team members and features robotics, airlocks and a new LIMS for digital data...
New Drug Protects Against Life-Threatening Pancreatitis
A new RNA‑based drug, plozasiran, received its first clinical validation for a rare inherited disorder that causes extreme blood‑fat accumulation and recurrent acute pancreatitis. In the PALISADE trial, a single injection every three months lowered the risk of pancreatitis by...
CRISPR Variant Selectively Targets Tumor DNA
Researchers at Van Andel Institute and Wageningen University have engineered a CRISPR variant, ThermoCas9, that reads DNA methylation patterns to differentiate tumor DNA from healthy DNA. The enzyme selectively cuts methylated cancer sequences while sparing unmethylated normal genes, a finding published...
Over-the-Counter Pet Flea Treatments Could Be Banned Under New UK Rules
The UK government has launched an eight‑week consultation to limit over‑the‑counter flea and tick treatments for cats and dogs to veterinary practitioners or pharmacists. The move targets pesticide‑based products containing fipronil and imidacloprid, which have been detected in the majority...
FDA Links Weight Loss Pill to ‘Unexpected’ Cardiovascular Risks
Eli Lilly’s oral GLP‑1 weight‑loss pill Foundayo (orforglipron) received FDA approval in early April, becoming the second oral GLP‑1 on the market after Novo Nordisk’s semaglutide. The agency’s approval letter, however, highlighted an unexpected serious risk of major adverse cardiovascular events, along...
InSPECt™ MS – Global HCP Profiling and Quantification by Native Digestion and LC-MS Analysis
The inSPECt™ MS platform combines native digestion with high‑resolution LC‑MS to quantify host‑cell proteins (HCPs) relative to spiked‑in protein standards. Calibration using the Cygnus Protein Standard demonstrated a linear response from 10 to 500 ppm with coefficients of variation under 18 %...
Researchers Find DMT Provides Longer-Lasting Antidepressant Effects than S-Ketamine in Animal Models
A recent Neuropharmacology study shows that a single dose of the psychedelic N,N‑dimethyltryptamine (DMT) produces rapid antidepressant effects in mice that last up to eight days, outperforming S‑ketamine’s shorter‑lived impact. Both compounds reversed learned‑helplessness behavior within 24 hours, but only...
Ultra- and Diafiltration Clear Leachables Effectively
A new study from the National Institute for Bioprocessing Research demonstrates that ultrafiltration and diafiltration (UF/DF) consistently remove over 98% of 24 out of 28 tested leachable compounds across three distinct protein processes. The clearance is largely driven by the...
IPSC-Based Manufacture Vs. Autologous Model Production Costs Examined via Financial Analysis
A new Cellistic white paper quantifies the cost advantage of using induced pluripotent stem cells (iPSCs) to manufacture NK cell therapies. The analysis shows cost of goods per dose can drop to roughly $5,000, a 95% reduction compared with $115,000...
Biopharma Adopting AI Despite Remaining GMP Compliance Questions
Biopharma firms are rapidly integrating artificial intelligence and machine learning into manufacturing, but regulatory‑compliant use cases remain a hurdle. Thermo Fisher’s senior director emphasizes that AI should augment, not replace, validated processes and must operate within a clear GMP framework....
This Pill May Help Pancreatic Cancer Patients Live Longer
Revolution Medicines announced that its RAS‑blocking pill daraxonrasib more than doubled median overall survival for patients with metastatic pancreatic cancer, extending it to 13.2 months versus 6.7 months on chemotherapy. The data will support an expedited FDA filing, and the...
In Vivo Autoimmune CAR-T Race Grows as Two RNA Startups Enter the Clinic
Two RNA‑focused biotech firms have entered human trials of in vivo CAR‑T therapies targeting autoimmune diseases. China’s Immorna reported its first systemic sclerosis patient treated with an RNA‑delivered CAR‑T that reduced peripheral B‑cell activity. A U.S. startup, GeneCure, launched a...
US FDA to Convene Expert Panel to Review Wider Access to some Peptides
The U.S. Food and Drug Administration announced it will convene an external advisory panel in July to decide whether licensed compounding pharmacies can resume manufacturing more than half a dozen peptides that were barred in 2023. The ban covered 14...
Former FDA Cancer Chief Pazdur Warns of the Political 'Breach' Of Review Teams
Richard Pazdur, who led the FDA’s oncology review program for more than two decades, stepped down in December after only a few weeks as director of the agency’s Center for Drug Evaluation and Research. In his departure, Pazdur warned that...
Novel Targets for Complex Cancer Revealed by Genetic Regulatory Node Mapping
Researchers at Rockefeller University unveiled PerturbFate, a single‑cell platform that maps how diverse genetic variations reshape cellular behavior over time. By profiling DNA accessibility, RNA output, and chromatin state in thousands of cells, the system identified common regulatory nodes that...
Compounding Quality Center of Excellence | Recorded Webinars
The requested article was not provided; only navigation links and a brief placeholder notice appeared. Consequently, there is no substantive news about a Compounding Quality Center of Excellence webinar to summarize. No author, date, or body content was available for...
Outsourcing Facilities Annual Study
The FDA’s Compounding Quality Center of Excellence released its annual Outsourcing Facilities study, surveying registered 503B facilities to gauge perceptions of FDA engagement, quality practices, and industry challenges. Findings show a stable number of facilities since 2019, wide variation in...
Pharma.Aero Studies Geopolitical Instability in the Gulf
Novo Nordisk’s flagship semaglutide drugs lost Indian patent protection, prompting a flood of low‑cost generics that slashed prices by up to 90%. At the same time, geopolitical turmoil in the Gulf has disrupted key air‑cargo corridors, affecting roughly 21.7% of...
Revolution Medicines Prices $2B Raise as XBI Reaches Heights Not Seen Since Pandemic
Revolution Medicines priced a $2 billion public offering, marking the biotech sector’s largest equity raise since the COVID‑19 pandemic. The capital raise follows a recent positive readout from the company’s late‑stage trial, boosting investor confidence. The move helped lift the SPDR...
Pediatric Tracking Requirements Under FDAAA
The Food and Drug Administration Amendments Act (FDAAA) now obligates the FDA to track and publicly release detailed pediatric data from clinical trials conducted under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. The agency aggregates...
Whitepaper: CDMOs at a Crossroads
The contract development and manufacturing organization (CDMO) sector is undergoing a rapid transformation as pharma and biotech firms chase end‑to‑end solutions for biologics, cell and gene therapies. Demand for specialized partnerships is rising alongside U.S. policies that encourage domestic production....
Obsidian, Galera to Advance Cell Therapy Following Reverse Merger
Obsidian Therapeutics will go public on Nasdaq via a reverse merger with Galera Therapeutics, creating a combined entity focused on OBX-115, a tumor‑infiltrating lymphocyte (TIL) cell therapy. OBX-115 is in mid‑stage melanoma and early‑stage lung‑cancer trials and is designed to...
BMS Makes a Beeline, Bringing 5 Assets to Biotech's $300M Precision Immunology Debut
Bristol Myers Squibb has spun out a new biotech, Beeline Medicines, backed by $300 million from Bain Capital and an initial portfolio of five assets. The company, led by former SpringWorks CEO Saqib Islam, will focus on precision therapies for autoimmune...
STAT+: Pharmalittle: We’re Reading About FDA Seeking More Data on a Lilly Obesity Pill, a Pharma 340B Win, and More
U.S. FDA has asked Eli Lilly to provide additional safety data on its newly approved obesity drug Foundayo, mandating post‑marketing trials for cardiovascular events, delayed gastric emptying, and a lactation study. The pill, a GLP‑1 agonist, received accelerated approval through the...
Eight Allergy Companies to Watch in 2026
The allergy‑treatment landscape is moving from symptom relief to disease‑modifying therapies, with eight biotech firms leading the charge in 2026. Allergy Therapeutics secured German approval for its short‑course Grassmuno vaccine, while Aravax bolstered its board ahead of a phase 3 launch...
Ads for GLP-1 Drugs Are Flooding the Internet – Here’s How to Know if It’s Safe to Buy Them Online
The surge in online advertisements for GLP‑1 weight‑loss drugs, amplified by a high‑profile Super Bowl commercial, has led many consumers to seek cheaper, compounded versions of medications like Ozempic and Wegovy. The FDA warns that these non‑brand products often bypass...
New Technique Maps Cancer Drug Uptake Inside Living Cells
Researchers at the University of Surrey and King's College London have unveiled a new analytical workflow that maps metal‑based cancer drugs inside living cells. By pairing SEISMIC capillary sampling with laser‑ablation ICP‑MS, they detected trace thallium—used as a surrogate for...
ARS Pharmaceuticals Reports Health Canada Approval of Neffy 2mg to Treat Type I Allergic Reactions
Health Canada has approved ARS Pharma’s neffy 2 mg adrenaline nasal spray for adults and children weighing over 30 kg, marking the first needle‑free emergency treatment for anaphylaxis in the country. In November 2024, ARS granted ALK exclusive rights to commercialize neffy...
Takeda Continues to Prune Partnerships, Cuts Ties with mRNA-Targeting Veritas In Silico
Takeda announced the termination of its three‑year partnership with Veritas In Silico, a collaboration focused on small‑molecule drugs that target mRNA. The split, confirmed on April 13, follows a recent wave of collaborator cuts, including a break with Denali Therapeutics and...
TOBY Secures US FDA Breakthrough Device Designation for Urine-Based Multi-Cancer Test
TOBY has received FDA Breakthrough Device Designation for its urine‑based Multi‑Cancer Early Detection (MCED) test. The non‑invasive platform analyzes volatile organic compounds in a single urine sample using spectroscopy and machine‑learning algorithms to identify multiple cancer types. The designation positions...
Bioadhesive Scaffold for Dual Delivery of Methotrexate‐Loaded Liposomes and Chondrogenic miRNA in Advanced Rheumatoid Arthritis Therapy
Researchers have engineered a bioadhesive scaffold that couples inflammation‑responsive methotrexate‑loaded liposomes with miRNA‑140‑bearing nanoparticles to treat advanced rheumatoid arthritis. The scaffold, composed of collagen, polydopamine‑modified hyaluronic acid and PEGDE cross‑linker, adheres to joint tissue, releases methotrexate when matrix metalloproteinases are...
Tumor Microenvironment‐Responsive Dual‐Enzymatic Flasklike Nanobots for Enhanced Chemotherapy
Researchers have engineered a flask‑shaped nanobot (GC‑M@FPNbot) that harnesses glucose oxidase and catalase to self‑propel in response to tumor‑specific proton and hydrogen peroxide gradients. Loaded with doxorubicin, the bots exhibit chemotactic motion that enables deep penetration of extracellular matrix and...
STAT+: New Bain Biotech Startup, Building on BMS Drugs, Gets a Name and a CEO
Bain Capital Life Sciences has launched a new biotech venture, Beeline Medicines, backed by a $300 million investment and five drug assets licensed from Bristol Myers Squibb. The startup will focus on inflammatory and immune‑mediated diseases, beginning with an oral candidate for...
Danish MinervaX Bolsters Executive Team Amid Transition to Pivotal Vaccine Trial Phase
Denmark‑based biotech MinervaX has hired Jamila Louahed, a former GSK vaccine R&D executive, as Chief Development Officer and veteran life‑science CFO Hans Henrik Chrois Christensen. The leadership changes come as the company prepares to launch a pivotal Phase III trial...
QIAGEN Launches QIAstat-Dx BCID GPF Plus AMR Panel for Bloodstream Infection Syndromic Testing
QIAGEN has launched the CE‑IVDR‑certified QIAstat‑Dx BCID GPF Plus AMR Panel for rapid bloodstream‑infection syndromic testing. The assay detects 20 gram‑positive bacterial and fungal targets and ten antimicrobial‑resistance markers, delivering results in approximately one hour. Announced at the ESCMID Global...
J&J Targets $100B Revenue, Replimune Rebuffed Again and a “Revolution” In Pancreatic Cancer
Johnson & Johnson reported $24.1 billion in first‑quarter sales and set an ambitious $100 billion revenue target for 2026, underscoring its aggressive growth strategy amid a wave of biotech M&A. Replimune’s advanced melanoma therapy RP1 was denied again, with the FDA insisting...
3H Labs Research: Steamed Ginger Extract Supports Weight Loss
A randomized, double‑blind, placebo‑controlled trial of 80 overweight adults found that daily 480 mg of 3H Labs' steamed ginger extract, Zinoact, significantly reduced body weight, body‑fat percentage, and waist circumference over 12 weeks. The extract, standardized to high levels of 1‑dehydro‑6‑gingerdione, also...
GlycoNex Secures Japan’s PMDA Approval for GNX1021 Phase I Trial
GlycoNex has secured approval from Japan’s Pharmaceuticals and Medical Devices Agency to launch a first‑in‑human Phase I study of its lead ADC, GNX1021, in advanced gastrointestinal cancers. The multi‑centre trial will begin patient enrollment in Japan by June 2026, with parallel IND...
A Molecular Movie Captures Cancer's Great Escape From Targeted Therapy
Researchers at the Institute for Systems Biology captured a "molecular movie" showing that melanoma cells enter a reversible, drug‑tolerant state within hours of BRAF‑targeted therapy. The study, published in Nature Communications, reveals an ordered two‑wave transcriptional program driven by NF‑κB‑mediated...
Can Europe Finance and Keep Its Biotech Winners?
The United States saw a surge of life‑sciences IPOs in early 2026, raising over $1 billion, while Europe continues to lose its biotech firms to foreign markets. Over the past six years, 66 of 67 EU biotech companies that went public...
Mending University and Venture Capital Relations: Is It Possible to See Eye-to-Eye?
European university spin‑outs in deep‑tech and life sciences now represent a $398 billion asset pool, but collaboration with venture capitalists remains fraught. Tech transfer offices are tasked with bridging divergent goals—academia’s focus on discovery and publications versus VCs’ demand for speed...
Partner Therapeutics Reports the US FDA sBLA Submission of Bizengri for NRG1 Fusion Positive Cholangiocarcinoma
Partner Therapeutics has filed a supplemental Biologics License Application (sBLA) with the U.S. FDA for Bizengri (zenocutuzumab‑zbco), a monoclonal antibody designed for adults with advanced unresectable or metastatic cholangiocarcinoma that carry an NRG1 gene fusion. The filing is supported by...
PreVenTB Trial: Considerations for Interpreting Extrapulmonary Tuberculosis Efficacy and Tuberculin Skin Test-Stratified Analyses
The PreVenTB phase‑3 trial evaluated the recombinant BCG vaccine VPM1002 and the subunit vaccine Immuvac in 12,700 Indian household contacts, but neither met the primary endpoint of preventing microbiologically confirmed tuberculosis. The authors noted a 23.1% versus 20.3% six‑month tuberculin...